

INDEX

Note: Entries followed by “f” indicate figures; “t” tables.

Symbols and Numbers

- α -3-Hydroxy-5-methyl-4-isooxazolopropionic acid/kainate antagonists. *See* AMPA (alpha-3-hydroxy-5-methyl-4-isooxazolopropionic acid)/kainate antagonists.
- α -Blockers, 44
- β -Blockers, 44, 45t, 153-154
- 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *See* HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A reductase) inhibitors.
- 4a-Phenamthrenamine derivatives, 270
- 4-S (Scandinavian Simvastatin Stroke Study), 49t

- Abciximab, 252
- Abdominal aortic aneurysm, 35
- ACAPS (Asymptomatic Carotid Artery Progression Study), 49t
- ACE (angiotensin-converting enzyme) inhibitors, 44-46, 45t, 153-154
- Acetaminophen, 150, 184
- Activity levels, 179-181, 180t-181t
- Acute stroke management (prevention, evaluation, and treatment) topics. *See also under individual topics.*
 - clinical trials and research studies. *See* Clinical trials and research studies.
 - diagnoses and evaluations, 69-101
 - drug therapies and drug-related considerations. *See* Drug therapies and drug-related considerations.
 - emergency medical management, 147-173
 - fundamental concepts, 13-19
 - hemorrhagic stroke management, 189-219
 - hospital admissions and general management, 175-188
 - imaging techniques (brain and blood vessels), 103-145
 - ischemic stroke acute management, 221-314
 - brain blood supply, 221-264
 - neuroprotection, 265-278
 - prevention measures and therapies, 279-314
 - overviews and summaries. *See* Overviews and summaries.
 - post-stroke rehabilitation, 315-320
 - prevention measures and therapies, 33-68, 279-314
 - general measures, 33-68
 - for ischemic and recurrent ischemic stroke, 279-314
 - reference resources. *See* Reference resources.
 - services organization, 21-32
- Acute stroke-care teams, 24-27, 26t

Adenosine receptor agonists, 268

Admissions, 175-188. *See also* Hospital admissions and general management.

Age-related risk factors, 34t

Airway and breathing support, 147-149

Akinetic segments, 36t

Albers, et al study, 231t

Alcohol consumption, excessive, 51-52, 193t, 287-290, 289t

Algorithms, 90f-95f, 282f-283f. *See also under individual topics.*
for diagnoses and evaluations, 90f-95f
for recurrent ischemic and ischemic stroke (prevention measures and therapies), 282f-283f

Alpha-3-hydroxy-5-methyl-4-isooxazolopropionic acid/kainate antagonists. *See* AMPA (alpha-3-hydroxy-5-methyl-4-isooxazolopropionic acid)/kainate antagonists.

Alpha-blockers, 44

Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke study. *See* ATLANTIS (Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke) study.

Alzheimer's disease, 13

Amaurosis fugax, 56-57

Amyloid angiopathy, 42t

AMPA (alpha-3-hydroxy-5-methyl-4-isooxazolopropionic acid)/kainate antagonists, 269-270

Amphetamines, 43t, 198

Amyloid angioplasty, central, 199

Analgesics, 184, 205t

Ancrod, 222t

Aneurysms, 35, 36t-37t, 42t, 203-211, 205t-206t, 208f-209f, 273-274
abdominal aortic, 35
aneurysmal rupture, 273-274
atrial septal, 36t
descriptions of, 36t-37t, 42t
fusiform (dolichoectatic), 37t
nonsaccular, 203-204
risk factors and, 36t-37t, 42t
saccular, 203-211, 205t-206t, 208f-209f
ventricular, 36t

Angina pectoris, 35

Angiotensin receptor blockers. *See* ARBs (angiotensin receptor blockers).

Angiotensin-converting enzyme inhibitors. *See* ACE (angiotensin-converting enzyme) inhibitors.

Antacids, 184-185, 293

Antibiotics, 183, 288, 289t

Anticoagulants, 25t, 43t, 81, 178t, 185-186, 190, 193-195, 193t, 196t, 221, 222t, 232, 241-250, 242t-243t, 246t-247t, 249t, 298-299

Anticoagulants, long-term, 280-281, 280t

Anticoagulants, oral, 194-195, 196t, 250, 281-291, 282f-283f, 284t-285t, 292

Anticonvulsants, 160, 205t

Antiemetic agents, 184, 205t

Antifibrinolytic agents, 205t, 207

Antihypertensive agents, 46, 155, 184, 205t-206t

Antiplatelet aggregate agents, 43t, 193-195, 196t, 221-223, 222t, 232, 250-252, 280-281, 280t, 291-298, 292t, 298-299

Antipyretics, 150

Antithrombotic agents, 154-155, 221-223

Aortic atherosclerosis, 37t

Apnea, sleep, 51-52

Aptiganel, 269270

ARBs (angiotensin receptor blockers), 44, 45t, 46

Argatroban, 222t

Arrhythmias, 150-151, 151t

Arterial hypertension, 151-158, 156t-157t
descriptions of, 151-152
long-term treatment initiation for, 155-158
treatment of, 153-155, 153t, 156t-157t

Arterial hypotension, 158

Aspirin, 150, 205t, 222t, 242t-243t, 246t-247t, 250-252, 280-281, 280t, 282f-283f, 287, 291-294, 292t

Aspirin, low dose, 282f-283f, 293-295, 298-299

Aspirin/clopidogrel, 195, 297-298, 298-299

Aspirin/dipyridamole, 194, 252, 280-281, 280t, 282f-283f, 294-295, 298-299

Asymptomatic Carotid Artery Progression Study. *See* ACAPS (Asymptomatic Carotid Artery Progression Study).

Asymptomatic cervical (carotid) stenosis or bruit, 54-56

Atherosclerotic causes, 35-43, 37t

ATLANTIS (Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke) study, 227-232

Atrial appendage thrombus, 36t

Atrial fibrillation, 36t, 53-54

Atrial lesions, 36t

Atrial septal aneurysm, 36t

Atrial septic defect, 36t

Atrial thrombus, 36t

Atrial turbulence, 36t

Atropine, 206t

Background perspectives, 13-14

Barbiturates, 272

Barthel Index, 225t-226t

- Basic concepts. *See* Fundamental concepts; Overviews and summaries.
- Basic FGF (basic fibroblastic growth factor), 270-271
- Beta-blockers, 44, 45t, 153-154
- Bezodiazepines, short-acting, 160
- Bladder care, 183
- Bleeding diatheses, 42t, 193-197, 193t, 197t
- Brain attack (stroke)-heart attack (myocardial infarction) difference summaries, 22t
- Brain blood supply, 221-264. *See also* Ischemic stroke acute management.
- anticoagulants, 241-250
 - antiplatelet agents, 250-252
 - embolectomy, 257
 - endovascular extraction of thrombus, 255-257
 - intervention summaries, 222t
 - nonpharmacologic surgical measures, 255-257
 - novel pharmacologic therapies, 254
 - overviews and summaries of, 221-223, 222t
 - pharmacologic thrombolysis, 223-240
 - reference resources for, 258-264
- Brain edema, 160-166, 163t
- Brain imaging techniques, 103-145. *See also* Imaging techniques (brain and blood vessels).
- Brain stem signs, 75t-76t
- Breathing and airway support, 147-149
- Bupropion, 51
- Calcium channel blockers, 44, 45t, 153-154, 266-268, 274
- Calcium channel blockers, L-type, 267-268
- Camerlingo, et al study, 242t-243t, 246t-247t
- Candesartan, 153
- Cardiac causes, 36t
- Cardiac complications, 150-151, 151t
- Cardioembolism, 35-40
- Cardiomyopathy, dilated, 36t
- Cardioversion, pharmacologic, 54
- CARE (Cholesterol and Recurrent Events) study, 49t
- Carotid circulation territories, 73t
- Carotid duplex scanning, 130-132, 133f
- Carotid endarterectomy, 300-303, 301t, 303t
- Centers of excellence, 23-24
- Central amyloid angioplasty, 199
- Cerebellum signs, 75t-76t
- Cerebral hemisphere infarction signs, 78t-79t
- Cerebral ischemia, secondary, 207-211
- Cerebrobasilar circulation territories, 73t
- Cerebrovascular accidents. *See* CVAs (cerebrovascular accidents).
- Cerebrovascular disease, 13
- Certoparin, 242t-243t, 246t-247t
- CGP-40116, 270
- CGS 19755, 270
- CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial, 251
- Chemotherapy, 200
- Cholesterol and Recurrent Events study. *See* CARE (Cholesterol and Recurrent Events) study.
- Choline, 270
- Cimetidine, 184-185
- Citicholine, 270
- Classes of Recommendations, 16t, 27, 44-52, 148-166, 198, 232, 284-304
- Class I, 16t, 27, 44-52, 148-159, 198, 232, 284-304
 - Class II, 16t
 - Class IIa, 16t, 51, 154-155, 159, 163-166, 285-286, 300-304
 - Class IIb, 16t, 47, 51-52, 285-286
 - Class III, 16t, 148-151, 154-155, 160, 162-166, 287
- overviews and summaries of, 16t
- Claudication, 35
- Clinical features, 70-75, 71t-75t. *See also* Diagnoses and evaluations.
- Clinical trials and research studies. *See also under individual topics.*
- 4-S, 49t
 - ACAPS, 49t
 - Albers, et al study, 231t
 - ATLANTIS study, 227-232
 - Camerlingo, et al study, 242t-243t, 246t-247t
 - CARE study, 49t
 - CHARISMA trial, 251
 - ECASS-1, 227-232, 228t
 - ECASS-2, 227-232
 - Eckert, et al study, 252
 - Egan, et al study, 231t
 - FISS, 242t-243t, 244-248, 246t-247t
 - FISS-bis, 242t-243t, 246-247t
 - Grond, et al study, 231t
 - HAEST, 242t-243t, 246t-247t
 - IST, 241-244, 242t-243t, 246t-247t
 - KAPS, 49t
 - Katzan, et al study, 231t
 - LIPID trial, 49t
 - MERCI trial, 255-257
 - NINDS studies, 224-236, 225t-226t, 229t
 - PROACT study, 237-240, 248-250

- Clinical trials and research studies (*continued*)
- PROACT-II study, 238-240
 - RAPID study, 242t-243t, 246t-247t
 - STAT parallel studies, 252
 - TAIST, 242t-243t, 246t-247t
 - Tanne, et al study, 231t
 - TOAST, 242t-243t, 246t-247t
 - TOPAS study, 242t-243t, 246t-247t
 - Wang, et al study, 231t
 - WARCEF trial, 286
 - WARSS trial, 248
 - WOSCOPS, 49t
- Clomethiazole, 268, 273
- Clopidogrel, 251-252, 280-281, 280t, 282f-283f, 292t, 296-298
- Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial. *See* CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial.
- Clopidogrel/aspirin, 195, 297-299
- Clumsy hand syndrome, 76t
- CNS 5161A, 270
- Coagulation disorders, 35
- Cocaine, 43t, 198
- Collaboration considerations, 21
- Common misconceptions, 14-15
- Common symptoms summaries, 22t
- Complications, 180t-181t, 184-185
 - summaries of, 180t-181t
 - treatment of, 184-185
- Computed tomography. *See* CT (computed tomography).
- Computed tomography angiography. *See* CTA (computed tomography angiography).
- Concomitant diseases, 184-185
- Contraceptives, oral, 34t, 51
- Corticosteroids, 162
- Coumarins, 250, 282f-283f, 284t-285t
- Crural paresis, 76t
- Crystalloids, 253-254
- CT (computed tomography), 103-118, 104t-107t, 108f, 110f-115f, 116t
- CTA (computed tomography angiography), 133-136, 135f-136f
- CVAs (cerebrovascular accidents), 14
- Cytidine, 270
- Cytidine diphosphocholine, 270
- Dalteparin, 242t-243t, 246t-247t
- Danaparoid, 222t, 242t-243t, 245-248, 246t-247t
- Deep vein thrombosis prevention, 185-186
- Dementia, 13, 193t, 289t
- Dementia, degenerative, 13
- Desmoteplase, 222t, 240
- Dextran, low molecular weight, 222t, 253-254
- Dextrorphan, 269-270
- Diabetes mellitus, insulin resistance, and metabolic syndrome, 46-47
- Diagnoses and evaluations, 69-101
 - algorithm for, 90f-95f
 - brain stem signs, 75t-76t
 - carotid circulation territories, 73t
 - cerebellum signs, 75t-76t
 - cerebral hemisphere signs, 76t
 - cerebrobasilar circulation territories, 73t
 - clinical features, 70-75, 71t-75t
 - diagnosis and treatment summaries, 17
 - diagnostic testing, 83-85, 84t-88t, 90f-95f
 - differential diagnoses, 69-70, 70t
 - emergency diagnostic studies summaries, 88t
 - general examinations, 75-80, 76t-80t
 - Glasgow Coma Scale, 87t
 - historical features, 71t
 - Hunt and Hess Scale, 86t
 - immediate evaluations, 80-83, 82t-83t
 - infarction signs, cerebral hemisphere, 78t-79t
 - ischemic vs hemorrhagic stroke features, 80t, 82t-83t
 - lacunar syndromes, 76t
 - localizing signs, 78t-79t
 - neurologic worsening causes, 72t
 - NIHSS, 85t
 - overview and summaries of, 69
 - reference resources for, 95-101
 - SAH signs, 84t, 86t
- Diatheses, bleeding, 42t, 193-197, 193t, 197t
- Digital subtraction angiography. *See* DSA (digital subtraction angiography).
- Dipyridamole, 292t
- Dipyridamole, extended-release, 298-299
- Dipyridamole/aspirin, 194, 252, 280-281, 280t, 282f-283f, 294-295, 298-299
- Direct thrombin inhibitors, 222t, 250, 290-291
- Diuretics and diuretic agents, 44, 45t, 46, 153-154, 182-183
- Dopamine, 158, 206t
- Drug abuse, 51-52, 193t, 198, 289t
- Drug therapies and drug-related considerations, 252, 298. *See also* under individual drug classes and names.
- α -blockers, 44

Drug therapies and drug-related considerations (*continued*)

β-blockers, 44, 45t, 153-154
4a-phemamthrenamine derivatives, 270
abciximab, 252
ACE inhibitors, 44, 45t, 46, 153-154
acetaminophen, 150, 184
adenosine receptor agonists, 268
AMPA/kainate antagonists, 269-270
amphetamines, 43t, 198
analgesics, 184, 205t
ancrod, 222t
antacids, 184-185, 293
antibiotics, 183, 288, 289t
anticoagulants, 25t, 43t, 81, 178t, 185-186, 190, 193-195, 193t, 196t, 221, 222t, 232, 241-250, 242t-243t, 246t-247t, 249t, 298-299
anticoagulants, long-term, 280-281, 280t
anticoagulants, oral, 194-195, 196t, 250, 281-291, 282f-283f, 284t-285t, 292
anticonvulsants, 160, 205t
antiemetic agents, 184, 205t
antifibrinolytic agents, 205t, 207
antihypertensive agents, 46, 155, 184, 205t-206t
antiplatelet aggregate agents, 43t, 193-195, 196t, 221-223, 222t, 232, 250-252, 280-281, 280t, 291-298, 292t, 298-299
antipyretics, 150
antithrombotic agents, 154-155, 221-223
aptiganel, 269270
ARBs, 44, 45t, 46
argatroban, 222t
aspirin, 150, 205t, 222t, 242t-243t, 246t-247t, 250-252, 280-281, 280t, 282f-283f, 287, 291-294, 292t
aspirin, low dose, 282f-283f, 293-295, 298-299
aspirin/clopidogrel, 195, 297-299
aspirin/dipyridamole, 194, 252, 280-281, 280t, 282f-283f, 294-295, 298-299
atropine, 206t
barbiturates, 272
basic FGF, 270-271
benzodiazepines, short-acting, 160
bupropion, 51
calcium channel blockers, 44, 45t, 153-154, 266-268, 274
calcium channel blockers, L-type, 267-268
candesartan, 153
cardioversion, pharmacologic, 54
certoparin, 242t-243t, 246t-247t
CGP-40116, 270

Drug therapies and drug-related considerations (*continued*)

CGS 19755, 270
chemotherapy, 200
choline, 270
cimetidine, 184-185
citicoline, 270
clomethiazole, 268, 273
clopidogrel, 251-252, 280-281, 280t, 282f-283f, 292t, 296-298
CNS 5161A, 270
cocaine, 43t, 198
contraceptives, oral, 34t, 51
corticosteroids, 162
coumarins, 250, 282f-283f, 284t-285t
crystalloids, 253-254
cytidine, 270
cytidine diphosphocholine, 270
dalteparin, 242t-243t, 246t-247t
danaparoid, 222t, 242t-243t, 245-248, 246t-247t
desmoteplase, 222t, 240
dextran, low molecular weight, 222t, 253-254
dextrophan, 269-270
dipyridamole, 292t
dipyridamole, extended-release, 298-299
direct thrombin inhibitors, 222t, 250, 290-291
diuretics and diuretic agents, 44, 45t, 46, 153-154, 182-183
dopamine, 158, 206t
eliprodil, 269-270
fibrinogen-depleting agents, 222t, 252
fibrinolytic agents, 221-223
fosphenytoin, 160
fraxiparin, 242t-243t, 244-248
free-radical scavengers, 273
furosemide, 163t, 164
GABA agonists, 268
gemfibrozil, 50
glutamate receptor antagonists, 266
glutamate release inhibitors, 268
glycerol, 164
GM1, 272
GP IIa/IIb inhibitors, 252, 298
GP IIa/IIb receptor blockers, 222t
GPI 3000, 270, 298
hemostatic medications, 191
heparin, 40t, 185-186, 196t, 222t, 238-244, 239t, 242t-243t, 246t-247t, 248-250, 249t
heparin, low molecular weight (LMWH), 222t, 244-248, 246t-247t, 289-290

Drug therapies and drug-related considerations (*continued*)

histamine antagonists, 184-185, 293
HMG-CoA inhibitors, 48, 49t
hydroxyethyl starch, 253-254
hypertonic saline, 163t, 164
ibuprofen, 150
insulin, 46-47, 69-70
labetalol, 155, 156t-157t
laxatives, 182-183
leukocyte-endothelial cell adhesion receptor inhibitors, 222t
licostinel, 269-270
lovastatin, 49t
lubeluzole, 268, 273
magnesium sulfate, 270
mannitol, 163t, 164
memantine, 270
membrane-active agents, 270
nadroparin, 242t-243t, 246t-247t
naloxone, 272
neuroprotectants-reperfusion combinations, 273
neuroprotective agents, 266
neurotrophic factors, 270-271
nicardipine, 155, 156t-157t
nicotine products (smoking cessation), 51
nifedipine, sublingual, 155
nimodipine, 206t, 211, 267-268, 273-274
nitrites, 44, 45t, 153-154
nitroglycerin, topical, 155
nitropaste, 156t-157t
nitroprusside. *See* Sodium nitroprusside.
NMDA antagonists, 269-270, 274
NO modulators, 271
nonagonist opiate receptor antagonists, 272
nonsteroidal anti-inflammatory agents, 205t
normal saline, 148t, 182-183
novel pharmacologic therapies, 254
NXY-059, 273
ondansetron, 184
opiates, 205t, 272
ORG 10172, 242t-243t
PAs, 221-237, 225t-226t, 228t-229t, 231t, 234f-235f, 240, 248-250, 249t, 255
phenylpropanolamine, 43t
phenytoin, 160
pioglitazone, 47
pravastatin, 49t
prourokinase, 222t, 237-240, 239t

Drug therapies and drug-related considerations (*continued*)

remacemide, 269-270
reteplase, 222t
r-Factor VIIa, 191
as risk factors, 42. *See also* Risk factors.
rt-PA/alteplase, 26t, 27-28, 91f, 154-155, 191, 222t, 223-238, 225t-226t, 228t-229t, 231t, 234f-235f, 240, 248-252, 249t, 255, 268, 273
saline, 254
saline, hypertonic, 163t, 164
saline, normal, 148t, 182-183
scu-PA, 222t
sedatives, 205t
selfotel, 269-270
S-emopamil, 267-268
simvastatin, 49t
sodium channel blockers, 268
sodium nitroprusside, 155, 156t-157t
statins, 48, 49t, 50
stimulants, 198
stool softeners, 182-183, 205t
streptokinase, 222t, 224
sulfipyrazone, 298
TGF- β , 270-271
thrombolytic agents, 43t, 81, 154-155, 190, 193t, 194-195, 196t, 201, 222t, 223-236, 225t-226t, 228t-229t, 231t, 234f-235f, 252, 274
thrombolytic agents, intra-arterial, 236-240, 239t
ticlopidine, 280-281, 280t, 282f-283f, 292t, 295-296
tinzaparin, 242t-243t, 246t-247t
tirilazad mesylate, 272
TNK, 222t, 240
tranquilizers, major, 184
triple-H therapy, 211
urokinase, 222t
vasoconstrictors, 222t, 254
vasodilators, 222t
vasopressors, 158, 206t, 222t, 254
VSCC antagonists, 266
VSCC blockers, N-type and T-type, 267-268
warfarin, 89, 280-281, 280t, 282f-283f, 284t-285t, 286, 292, 299
white cell receptor blockers, 254
ximelagatran, 290-291
ZK200775, 269-270
DSA (digital subtraction angiography), 136-140, 137f, 141t
Duplex scanning, carotid, 130-132, 133f
Dysarthria, 76t

ECASS-1 (European Cooperative Acute Stroke Study-1), 227-232, 228t

ECASS-2 (European Cooperative Acute Stroke Study-2), 227-232

EC/IC (extracranial-intracranial) bypass, 304

Eckert, et al study, 252

Edema, brain, 160-166, 163t

Egan, et al study, 231t

Electrocardiographic abnormalities, 150-151t

Eliprodil, 269-270

Embolectomy, 257

Emergency medical management, 147-173

- arterial hypertension, 151-158, 156t-157t
 - descriptions of, 151-152
 - long-term treatment initiation for, 155-158
 - treatment of, 153-155, 153t, 156t-157t
- arterial hypotension, 158
- brain edema, 160-166, 163t
- emergency diagnostic studies summaries, 88t
- emergency evaluation component summaries, 25-27
- emergency life-support, 147-151, 148t, 151t
 - airway and breathing support, 147-149
 - arrhythmias, 150-151, 151t
 - cardiac complications, 150-151, 151t
 - components of, 148t
 - electrocardiographic abnormalities and, 150-151t
 - fever, 149-150
 - hyperbaric oxygen, 149
- emergency medical services and. *See* EMSs (emergency medical services).
- for hemorrhagic stroke management, 190-191. *See also* Hemorrhagic stroke management.
- hyperglycemia vs hypoglycemia and, 158-159
- ICP, 160-166, 163t
- overviews and summaries of, 147
- palliative care and, 166
- papilledema, 161-162
- reference resources for, 167-173
- SAH, 159-160
- seizures, 159-160

EMSs (emergency medical services), 22t, 23-27, 25t-26t. *See also*

- Services organization.
- acute stroke-care teams, 24-27, 26t
- common symptoms summaries and, 22t
- emergency evaluation component summaries and, 25-27
- governmental support and, 23
- HMOs and, 24

EMSs (emergency medical services) (*continued*)

- Joint Commission on Accreditation Healthcare Organizations and, 23
- required field information summaries, 24-26, 25t
- stroke centers of excellence and, 23-24
- stroke (brain attack)-myocardial infarction (heart attack) difference summaries and, 22t

Enderectomy, carotid, 300-303, 301t, 303t

Endovascular extraction of thrombus, 255-257

Endovascular interventions, 305-307, 305t

Epidemiology and etiology, 13-14, 33-42, 34t

- epidemiologic risk factors, 33-35, 34t. *See also* Risk factors.
 - age, 34t
 - descriptions of, 33-35, 34t
 - family histories, 34t, 40-42
 - geography, 34t
 - race, 34t
- fundamental concepts, 13-14

Ethnic- and race-related risk factors, 34t

Etiology and epidemiology, 13-14. *See also* Epidemiology and etiology.

European Cooperative Acute Stroke Study-1. *See* ECASS-1 (European Cooperative Acute Stroke Study-1).

European Cooperative Acute Stroke Study-2. *See* ECASS-2 (European Cooperative Acute Stroke Study-2).

Evaluations and diagnoses, 69-101

- algorithm for, 90f-95f
- carotid circulation territories, 73t
- cerebellum signs, 75t-76t
- cerebral hemisphere infarction signs, 78t-79t
- cerebrobasilar circulation territories, 73t
- clinical features, 70-75, 71t-75t
- diagnosis and treatment summaries, 17
- emergency diagnostic studies summaries, 88t
- evaluation component summaries, 25-27
- general examinations, 75-80, 76t-80t
- Glasgow Coma Scale, 87t
- historical features, 71t
- Hunt and Hess Scale, 86t
- immediate evaluations, 80-83, 82t-83t
- ischemic vs hemorrhagic stroke features, 80t, 82t-83t
- lacunar syndromes, 76t
- localizing signs, 78t-79t
- neurologic worsening causes, 72t
- NIHSS, 85t
- overview and summaries of, 69
- reference resources for, 95-101
- SAH signs, 84t, 86t

Evidence levels. *See* Levels of Evidence.

Examinations, general, 75-80, 76t-80t. *See also* Diagnoses and evaluations.

Excessive alcohol consumption, 51-52

Exercise, lack of, 51-52

Extended-release dipyridamole, 298-299

Extracranial large-artery atherosclerosis, 37t

Extracranial-intracranial bypass. *See* EC/IC (extracranial-intracranial) bypass.

Extraction of thrombus, endovascular, 255-257

Family histories, 34t, 40-42

Features, clinical, 70-75, 71t-75t. *See also* Diagnoses and evaluations.

Female vs male risk factors, 34t, 40-42

Fever, 149-150

FGF, basic. *See* Basic FGF (basic fibroblastic growth factor).

Fibrinogen-depleting agents, 222t, 252

Fibrinolytic agents, 221-223

Field information summaries, 24-26, 25t

FISS (Fraxiparine Ischemic Stroke Study), 242t-243t, 244-248, 246t-247t

FISS-bis (second Fraxiparine Ischemic Stroke Study), 242t-243t, 246-247t

Fosphenytoin, 160

Four-S (Scandinavian Simvastatin Stroke Study), 49t

Fraxiparin, 242t-243t, 244-248

Fraxiparine Ischemic Stroke Study. *See* FISS (Fraxiparine Ischemic Stroke Study).

Fraxiparine Ischemic Stroke Study (second). *See* FISS-bis (second Fraxiparine Ischemic Stroke Study).

Free-radical scavengers, 273

Fundamental concepts, 13-19. *See also* Overviews and summaries.

- common misconceptions, 14-15
- diagnosis and treatment summaries, 17
- etiology and epidemiology, 13-14
- historical perspectives, 13-14
- Levels of Evidence and Classes of Recommendations, 16-17, 16t.

See also Classes of Recommendations; Levels of Evidence.

- management options summaries, 14-17, 16t
- overviews and summaries of, 13
- prevention summaries, 14-15
- reference resources for, 18-19

Fusiform (dolichoectatic) aneurysm, 37t

GABA (gamma-aminobutyric acid) agonists, 268

Gemfibrozil, 50

General examinations, 75-80, 76t-80t. *See also* Diagnoses and evaluations.

General management, 175-188. *See also* Hospital admissions and general management.

General observations and vital signs, 181

General prevention measures, 33-68. *See also* Prevention measures and therapies.

- overviews and summaries of, 33-35
- primary vs secondary prevention and, 33-35
- reference resources for, 59-68
- risk factors and, 33-52, 34t, 36t-40t, 42t-43t, 45t, 49-50t. *See also* Risk factors.

Geography-related risk factors, 34t

Glasgow Coma Scale, 25t, 87t

Glasgow Outcome Scale, 225t-226t

Glutamate receptor antagonists, 266

Glutamate release inhibitors, 268

Glycerol, 164

Glycoprotein (GP) IIA/IIB inhibitors, 252, 298

Glycoprotein (GP) IIA/IIB receptor blockers, 222t

GM1 (monosialoganglioside), 272

Governmental support, 23

GP (glycoprotein) IIA/IIB inhibitors, 252, 298

GP (glycoprotein) IIA/IIB receptor blockers, 222t

GPI 3000, 270, 298

Grond, et al study, 231t

HAEST (Heparin Aspirin Ischemic Stroke Trial), 242t-243t, 246t-247t

Heart attack (myocardial infarction)-brain attack (stroke)

- difference summaries, 22t

Hematologic risk factors, 40t

Hemorrhagic infection, secondary, 199-201

Hemorrhagic stroke management, 189-219

- causation management and prevention, 192-211. *See also* Prevention measures and therapies.
- bleeding diatheses, 193-197, 193t, 197t
- central amyloid angioplasty, 199
- drug abuse, 198
- hypertensive hemorrhage, 192-193
- nonsaccular aneurysms, 203-204
- rebleeding prevention, 205-207
- saccular aneurysms, 203-211, 205t-206t, 208f-209f
- SAH, 203-211, 205t-206t, 208f-209f
- secondary cerebral ischemia, 207-211
- tumors, 197
- vascular malformations, 201-203
- vasculitis, 197-198
- vasospasm prevention, 206t, 207-211
- venous thrombosis with secondary hemorrhagic infection, 199-201

- Hemorrhagic stroke management (*continued*)
 emergency management, 190-191. *See also* Emergency medical management.
 descriptions of, 190
 hemostatic medications, 190
 surgical management, hematomas, 190
 hemorrhagic vs ischemic stroke features, 80t, 82t-83t
 overviews and summaries of, 189-190
 reference resources for, 212-219
- Hemorrhagic transformation of infarction, 42t
- Hemostatic medications, 190, 191
- Heparin, 40t, 185-186, 196t, 222t, 238-244, 239t, 242t-243t, 246t-247t, 248-250, 249t
- Heparin Aspirin Ischemic Stroke Trial *See* HAEST (Heparin Aspirin Ischemic Stroke Trial).
- Heparin, low molecular weight (LMWH), 222t, 244-248, 246t-247t, 289-290
- Highest risk factors, 53-59, 58t-63t. *See also* Risk factors.
 amaurosis fugax, 56-57
 asymptomatic cervical (carotid) stenosis or bruit, 54-56
 atrial fibrillation, 53-54
 descriptions of, 53
 TIA, 56-57, 58t-61t
 warning leak, 57-59, 62t-63t
- Histamine antagonists, 184-185, 293
- Historical features, 71t. *See also* Diagnoses and evaluations.
- Historical perspectives, 13-14
- HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A reductase) inhibitors, 48, 49t
- HMOs (health maintenance organizations), 24
- Homolateral ataxia, 76t
- Hospital admissions and general management, 175-188
 activity levels, 179-181, 180t-181t
 bladder care, 183
 complications, 180t-181t, 184-185
 summaries of, 180t-181t
 treatment of, 184-185
 concomitant diseases, 184-185
 deep vein thrombosis prevention, 185-186
 general management, 176-179, 178t-179t
 hypovolemia and, 182-183
 multidisciplinary management, 178t-179t
 neurologic worsening causes, 176t
 nutrition and hydration, 182-183
 overviews and summaries of, 175-176, 176t
 pulmonary embolism prevention, 185-186
 reference resources for, 187-188
- Hospital admissions and general management (*continued*)
 rehabilitation, 186
 SIADH and, 182-183
 symptomatic management, 184
 vital signs and general observations, 181
- Hunt and Hess Scale, 86t
- Hydration and nutrition, 182-183
- Hydroxyethyl starch, 253-254
- Hyperbaric oxygen, 149
- Hypercholesterolemia, 47-50, 49t
- Hyperglycemia vs hypoglycemia, 158-159
- Hyperhomocysteinemia, 51-52
- Hypertension, arterial, 151-158, 156t-157t
- Hypertensive hemorrhage, 192-193
- Hypertonic saline, 163t, 164. *See also* Saline.
- Hypoglycemia vs hyperglycemia, 158-159
- Hypotension, arterial, 158
- Hypothermia, 271-273
- Hypovolemia, 182-183
- Ibuprofen, 150
- ICP (increased intracranial pressure), 160-166, 163t
- Imaging techniques (brain and blood vessels), 103-145
 brain imaging, 103-129
 carotid duplex scanning, 130-132, 133f
 CT, 103-118, 104t-107t, 108f, 110f-115f, 116t
 CTA, 133-136, 135f-136f
 DSA, 136-140, 137f, 141t
 MRA, 133-134, 134f
 MRI, 118-129, 120f, 122t-123t, 124f-127f, 128t, 129t
 MRV, 133-134, 134f
 overviews and summaries of, 103, 104t-105t
 PC sequences, 132-133
 PI, 140
 reference resources for, 142-145
 TCD ultrasonography, 130-132, 133f
 TOF sequences, 132-133
 vascular imaging, 129-140
- Immediate evaluations, 80-83, 82t-83t. *See also* Diagnoses and evaluations.
- Increased intracranial pressure. *See* ICP (increased intracranial pressure).
- Insulin, 46-47, 69-70
- Insulin resistance. *See* Diabetes mellitus, insulin resistance, and metabolic syndrome.
- Interarterial lesions, 36t
- International Stroke Trial *See* IST (International Stroke Trial).

- Intervention summaries, 222t
- Intra-arterial thrombolytic agents, 236-240, 239t. *See also* Thrombolytic agents.
- Intraatrial lesions, 36t
- Intracranial causes, 42t
- Intraventricular lesions, 36t
- Intraventricular thrombus, 36t
- Introductory concepts; Overviews and summaries. *See* Fundamental concepts; Overviews and summaries.
- Ischemic stroke acute management, 221-314. *See also under individual topics.*
- brain blood supply, 221-264
 - anticoagulants, 241-250
 - antiplatelet agents, 250-252
 - embolectomy, 257
 - endovascular extraction of thrombus, 255-257
 - intervention summaries, 222t
 - nonpharmacologic surgical measures, 255-257
 - novel pharmacologic therapies, 254
 - overviews and summaries of, 221-223, 222t
 - pharmacologic thrombolysis, 223-240
 - reference resources for, 258-264
 - neuroprotection, 265-278
 - AMPA antagonists, 269-270
 - aneurysmal rupture, 273-274
 - calcium channel blockers, 267-268
 - free-radical scavengers, 273
 - glutamate release inhibitors, 268
 - hypothermia, 271-273
 - membrane-active agents, 270
 - neurotrophic factors, 270-271
 - NMDA antagonists, 269-270
 - NO modulation, 271
 - novel interventions, 272-273
 - overviews and summaries of, 256-267
 - reference resources for, 275-278
 - SAH, 273-274
 - window of treatment, 274-275
 - prevention measures and therapies, 279-314
 - endovascular interventions, 305-307, 305t
 - general measures for, 279-280
 - medications for, 280-298
 - overviews and summaries of, 279
 - reference resources for, 307-314
 - surgical procedures for, 299-304
- Isolated sensory/motor stroke, 76t
- IST (International Stroke Trial), 241-244, 242t-243t, 246t-247t
- Joint Commission on Accreditation Healthcare Organizations, 23-24
- KAPS (Kuopio Atherosclerosis Prevention Study), 49t
- Katzan, et al study, 231t
- Kuopio Atherosclerosis Prevention Study. *See* KAPS (Kuopio Atherosclerosis Prevention Study).
- Labetalol, 155, 156t-157t
- Lack of exercise, 51-52
- Lacunar syndromes, 76t
- Lacunes, 35
- Large-artery atherosclerosis, 35
- Laxitives, 182-183
- Left atrial lesions, 36t
- Left ventricular lesions, 36t
- Leukocyte-endothelial cell adhesion receptor inhibitors, 222t
- Levels of Evidence, 16t, 27-52, 148-166, 198, 232, 284-304
- Level A, 16t, 27-29, 44-52, 158-159, 232, 284-304
 - Level B, 16t, 51-52, 148-151, 154-155, 159, 162-166, 198, 285-286, 300-304
 - Level C, 16t, 47, 51, 148-151, 154-155, 160
- overviews and summaries of, 16-17, 16t
- Libman-Sacks endocarditis, 36t
- Licostinel, 269-270
- Life-support, emergency, 147-151, 148t, 151t. *See also* Emergency medical management.
- airway and breathing support, 147-149
 - arrhythmias, 150-151, 151t
 - cardiac complications, 150-151, 151t
 - components of, 148t
 - electrocardiographic abnormalities and, 150-151t
 - fever, 149-150
 - hyperbaric oxygen, 149
- LIPID (Long-term Intervention With Pravastatin in Ischemic Disease) trial, 49t
- Lipophyalinosis, 37t
- LMW (low molecular weight) dextran, 222t, 253-254
- LMWH (low molecular weight heparin), 222t, 244-248, 246t-247t, 289-290. *See also* Heparin.
- Localizing signs, 78t-79t. *See also* Diagnoses and evaluations.
- Long-term anticoagulants, 280-281, 280t. *See also* Anticoagulants.
- Long-term Intervention With Pravastatin in Ischemic Disease. *See* LIPID (Long-term Intervention With Pravastatin in Ischemic Disease) trial
- Long-term treatment initiation, 155-158
- Lovastatin, 49t
- Low dose aspirin, 282f-283f, 293-295, 298-299. *See also* Aspirin.

- Low molecular weight dextran, 222t, 253-254
- Low molecular weight heparin (LMWH), 222t, 244-248, 246t-247t, 289-290
- L-type calcium channel blockers, 267-268
- Lubeluzole, 268, 273
- Magnesium sulfate, 270
- Magnetic resonance angiography. *See* MRA (magnetic resonance angiography).
- Magnetic resonance imaging. *See* MRI (magnetic resonance imaging).
- Magnetic resonance venography. *See* MRV (magnetic resonance venography).
- Major tranquilizers, 184
- Malabsorption cautions, 289t
- Male vs female risk factors, 34t, 40-42
- Malformations, vascular, 201-203
- Management of stroke (prevention, evaluation, and treatment) topics. *See also under individual topics.*
- brain and blood vessel imaging techniques, 103-145
 - clinical trials and research studies. *See* Clinical trials and research studies.
 - diagnoses and evaluations, 69-101
 - drug therapies and drug-related considerations. *See* Drug therapies and drug-related considerations.
 - emergency medical management, 147-173
 - fundamental concepts, 13-19
 - hemorrhagic stroke management, 189-219
 - hospital admissions and general management, 175-188
 - ischemic stroke acute management, 221-314
 - brain blood supply, 221-264
 - neuroprotection, 265-278
 - prevention measures and therapies, 279-314
 - overviews and summaries. *See* Overviews and summaries.
 - post-stroke rehabilitation, 315-320
 - prevention measures and therapies, 33-68, 279-314
 - general measures, 33-68
 - for ischemic and recurrent ischemic stroke, 279-314
 - reference resources. *See* Reference resources.
 - services organization, 21-32
- Mannitol, 163t, 164
- Mechanical Embolus Removal in Cerebral Ischemia. *See* MERCI (Mechanical Embolus Removal in Cerebral Ischemia) trial.
- Medications. *See* Drug therapies and drug-related considerations.
- Memantine, 270
- Membrane-active agents, 270
- MERCI (Mechanical Embolus Removal in Cerebral Ischemia) trial, 255-257
- Metabolic syndrome. *See* Diabetes mellitus, insulin resistance, and metabolic syndrome.
- Microatheroma, 37t
- Migraine, 51-52
- Mineral supplementation. *See* Supplements (vitamins, minerals, etc).
- Misconceptions, common, 14-15
- Mitral annulus calcification, 36t
- Modifiable risk factors, 34t, 43-52, 45t, 49t-50t. *See also* Risk factors.
- alcohol consumption, excessive, 51-52
 - apnea, sleep, 51-52
 - descriptions of, 34t, 43
 - drug abuse, 51-52
 - exercise, lack of, 51-52
 - hypercholesterolemia, 47-50, 49t
 - hyperhomocysteinemia, 51-52
 - hypertension, 43-46, 45t
 - migraine, 51-52
 - obesity, 51-52
 - oral contraceptive use, 51-52
 - sleep disorders, 51-52
- Modified Rankin Scale, 225t-226t
- Monocular blindness, transient, 56-57
- Monosialoganglioside (GM1), 272
- MRA (magnetic resonance angiography), 133-134, 134f
- MRI (magnetic resonance imaging), 118-129, 120f, 122t-123t, 124f-127f, 128t, 129t
- MRV (magnetic resonance venography), 133-134, 134f
- Multidisciplinary management, 178t-179t
- Mural thrombus, 36t
- Myocardial infarction (heart attack)-stroke (brain attack) difference summaries, 22t, 34t, 35, 40-42
- Myxoma, 36t
- Nadroparin, 242t-243t, 246t-247t
- Naloxone, 272
- National Institutes of Health Stroke Scale. *See* NIHSS (National Institutes of Health Stroke Scale).
- National Institutes of Neurological Disorders and Stroke. *See* NINDS (National Institutes of Neurological Disorders and Stroke) studies.
- Neoplasm, 42t. *See also* Tumors.
- Neurologic worsening causes, 72t, 176t
- Neuroprotectants-reperfusion combinations, 273

Neuroprotection, 265-278. *See also* Ischemic stroke acute management.

- AMPA antagonists, 269-270
- aneurysmal rupture, 273-274
- calcium channel blockers, 267-268
- free-radical scavengers, 273
- glutamate release inhibitors, 268
- hypothermia, 271-273
- membrane-active agents, 270
- neurotrophic factors, 270-271
- NMDA antagonists, 269-270
- NO modulation, 271
- novel interventions, 272-273
- overviews and summaries of, 256-267
- reference resources for, 275-278
- SAH, 273-274
- window of treatment, 274-275

Neuroprotective agents, 266

Neurotrophic factors, 270-271

Nicardipine, 155, 156t-157t

Nicotine products (smoking cessation), 51

Nifedipine, sublingual, 155

NIHSS (National Institutes of Health Stroke Scale), 26t, 85t, 225t-226t, 238-240, 249t

Nimodipine, 206t, 211, 267-268, 273-274

NINDS (National Institutes of Neurological Disorders and Stroke) studies, 224-236, 225t-226t, 229t

Nitric oxide modulators. *See* NO (nitric oxide) modulators.

Nitrites, 44, 45t, 153-154

Nitroglycerin, topical, 155

Nitropaste, 156t-157t

Nitroprusside. *See* Sodium nitroprusside.

NMDA (N-methyl-D-aspartate) antagonists, 269-270, 274

NO (nitric oxide) modulators, 271

Nonagonist opiate receptor antagonists, 272

Nonatherosclerotic vasculopathies, 35

Nonpharmacologic surgical measures, 255-257

Nonsaccular aneurysms, 203-204

Nonsteroidal anti-inflammatory agents, 205t

Normal saline, 148t, 182-183. *See also* Saline.

Novel pharmacologic therapies, 254

N-type and T-type VSCC (voltage-sensitive calcium channel) blockers, 267-268

Nutrition and hydration, 182-183

NXY-059, 273

Obesity, 51-52

Observations, general, 181

Ondansetron, 184

Opiates, 205t, 272

Oral anticoagulants, 194-195, 196t, 250, 281-291, 282f-283f, 284t-285t, 292. *See also* Anticoagulants.

Oral contraceptives, 34t, 51-52

ORG 10172, 242t-243t

Organization of services, 21-32

- collaboration considerations for, 21
- EMSs, 22t, 23-27, 25t-26t
 - acute stroke-care teams, 24-27, 26t
 - common symptoms summaries and, 22t
 - emergency evaluation component summaries and, 25-27
 - governmental support and, 23
 - HMOs and, 24
 - Joint Commission on Accreditation Healthcare Organizations and, 23
 - required field information summaries, 24-26, 25t
 - stroke centers of excellence and, 23-24
 - stroke (brain attack)-myocardial infarction (heart attack) difference summaries and, 22t

Overviews and summaries. *See also under individual topics.*

- of diagnoses and evaluations, 69
- of emergency medical management, 147
- of fundamental concepts, 13
- of hemorrhagic stroke management, 189-190
- of hospital admissions and general management, 175-176, 176t
- of imaging techniques (brain and blood vessels), 103, 104t-105t, 221-223, 222t
- of ischemic stroke acute management, 221-223, 222t, 256-267, 279
- neuroprotection, 256-267
 - prevention measures and therapies, 279
- of prevention measures and therapies, 33-35, 279
 - general measures, 33-35
 - ischemic and recurrent ischemic stroke, 279
- of services organization, 21

Oxygen, hyperbaric, 149

Palliative care, 166

Papilledema, 161-162

PAs (plasminogen activators), 221-237, 225t-226t, 228t-229t, 231t, 234f-235f, 240, 248-250, 249t, 255

Patent foramen ovale, 36t

PC (phase contrast) sequences, 132-133

Perfusion imaging. *See* PI (perfusion imaging).

Pharmacologic therapies. *See* Drug therapies and drug-related considerations.

Phase contrast sequences. *See* PC (phase contrast) sequences.
Phenylpropranolamine, 43t
Phenytoin, 160
PI (perfusion imaging), 140
Pioglitazone, 47
Plasminogen activators. *See* PAs (plasminogen activators).
Post-stroke rehabilitation, 315-320
 discharge planning and, 315, 318
 overviews and summaries of, 315
 patient education and, 315
 reference resources for, 318-320
 rehabilitation specialists, 315-318
 acute care setting-outpatient/inpatient setting transitions, 316-317
 constraint-induced movement therapy and, 317
 occupational therapists, 316
 physical therapists, 316
 roles of, 315-318
 speech pathologists, 316
 rehabilitation specialists roles in, 315-318
Pravastatin, 49t
Prevention measures and therapies, 33-68, 279-314. *See also under individual topics.*
 for deep vein thrombosis prevention, 185-186
 fundamental concepts of, 14-15
 general measures, 33-68
 overviews and summaries of, 33-35
 primary vs secondary prevention and, 33-35
 reference resources for, 59-68
 risk factors and, 33-52, 34t, 36t-40t, 42t-43t, 45t, 49-50t. *See also* Risk factors.
 for hemorrhagic stroke management, 192-211. *See also* Hemorrhagic stroke management.
 for ischemic and recurrent ischemic stroke, 279-314
 endovascular interventions, 305-307, 305t
 general measures for, 279-280
 medications for, 280-298
 overviews and summaries of, 279
 reference resources for, 307-314
 surgical procedures for, 299-304
 for pulmonary embolism, 185-186
 for vasospasm, 206t, 207-211
Primary vs secondary prevention, 33-35. *See also* Prevention measures and therapies.
PROACT (Prolyse in Acute Cerebral Thromboembolism) study, 237-240, 248-250
PROACT-II (Prolyse in Acute Cerebral Thromboembolism-II) study, 238-240

Prolyse in Acute Cerebral Thromboembolism. *See* PROACT (Prolyse in Acute Cerebral Thromboembolism) study.
Prolyse in Acute Cerebral Thromboembolism-II study. *See* PROACT-II (Prolyse in Acute Cerebral Thromboembolism-II) study.
Prourokinase, 222t, 237-240, 239t
Pulmonary embolism prevention, 185-186
Pure motor hemiparesis, 76t
Pure sensory stroke, 76t

Race- and ethnic-related risk factors, 34t
Rankin Scale, Modified, 225t-226t
RAPID (Rapid Anticoagulation Prevents Ischemic Damage) study, 242t-243t, 246t-247t
Rebleeding prevention, 205-207
Recombinant activated Factor VII. *See* r-Factor VIIa (recombinant activated Factor VII).
Recombinant tissue plasminogen activator. *See* rt-PA/alteplase (recombinant tissue plasminogen activator).
Recommendation classes. *See* Classes of Recommendations.
Recurrent ischemic and ischemic stroke (prevention measures and therapies), 279-314. *See also* Prevention measures and therapies.
 algorithm for, 282f-283f
 general measures for, 279-280
 medications for, 280-298. *See also* Drug therapies and drug-related considerations.
 anticoagulants, oral, 281-285, 285t
 antiplatelet agents, 291-298, 292t
 arterial diseases and, 287
 aspirin, 291-294
 cardioembolic stroke and, 284-286, 284t
 coagulation disorders and, 286
 clopidogrel, 296-298
 descriptions of, 280-281, 280t
 dipyridamole and aspirin/dipyridamole, 294-295
 direct thrombin inhibitors, 290-291
 GP IIa/IIb inhibitors, 298-299
 potential complications of, 287-290, 289t
 sulfinpyrazone, 298-299
 ticlopidine, 295-296
 overviews and summaries of, 279
 reference resources for, 307-314
 surgical procedures for, 300-305, 301t, 303t, 305t
 carotid endarterectomy, 300-303, 301t, 303t
 descriptions of, 299-300
 endovascular interventions, 305-307, 305t
 revascularization operations, 304

Recurrent ischemic and ischemic stroke (prevention measures and therapies), surgical procedures for (*continued*)
superficial temporal artery to middle cerebral artery anastomosis (extracranial-intracranial [EC/IC] bypass), 304

Reference resources. *See also under individual topics.*
for diagnoses and evaluations, 95-101
for emergency medical management, 167-173
for fundamental concepts, 18-19
for hemorrhagic stroke management, 212-219
for hospital admissions and general management, 187-188
for imaging techniques (brain and blood vessels), 142-145
for ischemic stroke acute management, 258-264, 275-278, 307-314
brain blood supply, 258-264
neuroprotection, 275-278
prevention measures and therapies, 307-314
for prevention measures and therapies, 59-68, 307-314
general measures, 59-68
ischemic and recurrent ischemic stroke, 307-314
for services organization, 29-32

Rehabilitation, 186

Remacemide, 269-270

Reperfusion-neuroprotectants combinations, 273

Required field information summaries, 24-26, 25t

Research studies. *See* Clinical trials and research studies.

Retepase, 222t

Revascularization operations, 304

r-Factor VIIa (recombinant activated Factor VII), 191

Risk factors, 33-52, 34t, 36t-40t, 42t-43t, 45t, 49-50t. *See also* Prevention measures and therapies.
amyloid angiopathy, 42t
aneurysm, 36t-37t, 42t
atherosclerotic causes, 35-43, 37t
bleeding diatheses, 42t
cardiac causes, 36t
cardioembolism, 35-40
coagulation disorders, 35, 40t
drugs and pharmacologic agents, 42
epidemiologic, 33-35, 34t
age, 34t
descriptions of, 33-35, 34t
family histories, 34t, 40-42
geography, 34t
race, 34t
sex, 34t, 40-42
hematologic, 40t
hemorrhagic transformation of infarction, 42t

Risk factors (*continued*)
highest, 53-59, 58t-63t
amaurosis fugax, 56-57
asymptomatic cervical (carotid) stenosis or bruit, 54-56
atrial fibrillation, 53-54
descriptions of, 53
TIA, 56-57, 58t-61t
warning leak, 57-59, 62t-63t
intracranial causes, 42t
large-artery atherosclerosis, 35
modifiable, 34t, 43-52, 45t, 49t-50t
alcohol consumption, excessive, 51-52
apnea, sleep, 51-52
descriptions of, 34t, 43
diabetes mellitus, insulin resistance, and metabolic syndrome, 46-47
drug abuse, 51-52
exercise, lack of, 51-52
hypercholesterolemia, 47-50, 49t
hyperhomocysteinemia, 51-52
hypertension, 43-46, 45t
migraine, 51-52
obesity, 51-52
oral contraceptive use, 51-52
sleep disorders, 51-52
smoking, 50-51
neoplasm, 42t
nonatherosclerotic vasculopathies, 35, 38t-39t
overviews and summaries of, 33-35, 34t
primary vs secondary prevention and, 33-35. *See also* Prevention measures and therapies.
small-artery occlusive diseases (lacunes), 35
trauma, 42t
vascular malformation, 42t
vasculitis, 42t
venous thrombosis, 42t

rt-PA/alteplase (recombinant tissue plasminogen activator), 26t, 27-28, 91f, 154-155, 191, 222t, 223-238, 225t-226t, 228t-229t, 231t, 234f-235f, 240, 248-252, 249t, 255, 268, 273

Rupture, aneurysmal, 273-274

Saccular aneurysms, 203-211, 205t-206t, 208f-209f

SAH (subarachnoid hemorrhage), 84t, 86t, 159-160, 203-211, 205t-206t, 208f-209f, 273-274

Saline, 254

Saline, hypertonic, 163t, 164

Saline, normal, 148t, 182-183

Scandinavian Simvastatin Stroke Study. *See* 4-S (Scandinavian Simvastatin Stroke Study).

Scavengers, free-radical, 273

scu-PA (single-chain urokinase plasminogen activator), 222t. *See also* PAs (plasminogen activators).

Second Fraxiparine Ischemic Stroke Study. *See* FISS-bis (second Fraxiparine Ischemic Stroke Study).

Secondary cerebral ischemia, 207-211

Secondary hemorrhagic infection, 199-201

Secondary prevention vs primary prevention, 33-35. *See also* Prevention measures and therapies.

Sedatives, 205t

Segments, akinetic, 36t

Seizures, 159-160

Selected readings. *See* Reference resources.

Selfotel, 269-270

S-emopamil, 267-268

Services organization, 21-32

- collaboration considerations for, 21
- EMSs, 22t, 23-27, 25t-26t
 - acute stroke-care teams, 24-27, 26t
 - common symptoms summaries and, 22t
 - emergency evaluation component summaries and, 25-27
 - governmental support and, 23
 - HMOs and, 24
 - Joint Commission on Accreditation Healthcare Organizations and, 23
 - required field information summaries, 24-26, 25t
 - stroke centers of excellence and, 23-24
 - stroke (brain attack)-myocardial infarction (heart attack) difference summaries and, 22t
 - third-party payers support and, 23
 - overviews and summaries of, 21
 - public education and responses, 21-23, 22t
 - common symptoms awareness and recognition, 21-23, 22t
 - correct responses, 21-23
 - EDs and, 21-23
 - reference resources for, 29-32
 - stroke units, 26t, 27-29, 28t
 - benefits of, 27
 - components of, 28t
 - definitions of, 27-28
 - ICUs and, 28-29
 - NIHSS score determinations and, 26t
 - step-down unit concept of, 28-29
 - success of, 27-29
- Sex-related risk factors, 34t, 40-42
- Shagbark aorta, 37t
- Short-acting benzodiazepines, 160
- SIADH (syndrome of inappropriate secretion of antidiuretic hormone), 182-183
- Sign descriptions and summaries. *See* Diagnoses and evaluations.
- Simvastatin, 49t
- Single-chain urokinase plasminogen activator. *See* scu-PA (single-chain urokinase plasminogen activator).
- Sleep apnea and other sleep disorders, 51-52
- Small-artery disease, 37t
- Small-artery occlusive diseases (lacunes), 35
- Smoking, 50-51
- Sodium channel blockers, 268
- Sodium nitroprusside, 155, 156t-157t
- STAT parallel studies (North American and European), 252
- Statins, 48, 49t, 50. *See also under individual drug names.*
- Stimulants, 198
- Stool softeners, 182-183, 205t
- Streptokinase, 222t, 224
- Stroke centers of excellence, 23-24
- Stroke management (prevention, evaluation, and treatment) topics. *See also under individual topics.*
 - brain and blood vessel imaging techniques, 103-145
 - clinical trials and research studies. *See* Clinical trials and research studies.
 - diagnoses and evaluations, 69-101
 - drug therapies and drug-related considerations. *See* Drug therapies and drug-related considerations.
 - emergency medical management, 147-173
 - fundamental concepts, 13-19
 - hemorrhagic stroke management, 189-219
 - hospital admissions and general management, 175-188
 - imaging techniques (brain and blood vessels), 103-145
 - ischemic stroke acute management, 221-314
 - brain blood supply, 221-264
 - neuroprotection, 265-278
 - prevention measures and therapies, 279-314
 - overviews and summaries. *See* Overviews and summaries.
 - post-stroke rehabilitation, 315-320
 - prevention measures and therapies, 33-68, 279-314
 - general measures, 33-68
 - for ischemic stroke, 279-314
 - reference resources. *See* Reference resources.
 - services organization, 21-32
- Stroke (brain attack)-myocardial infarction (heart attack) difference summaries, 22t
- Stroke services organization, 21-32. *See also* Services organization.

Studies, research. *See* Clinical trials and research studies.
 Subarachnoid hemorrhage. *See* SAH (subarachnoid hemorrhage).
 Sublingual nifedipine, 155
 Suggested readings. *See* Reference resources.
 Sulfinpyrazone, 298-299
 Summary topics. *See* Overviews and summaries.
 Superficial temporal artery to middle cerebral artery anastomosis, 304
 Supplements (vitamins, minerals, etc.). *See also under individual supplement names.*
 calcium, 45t
 folic acid, 51-52
 magnesium, 45t
 niacin, 50
 potassium, 45t, 182-183
 pyridoxine, 51-52
 vitamin B₁₂, 51-52
 vitamin K, 281, 288, 289t
 Surgical procedures, 255-257, 300-305, 301t, 303t, 305t
 carotid endarterectomy, 300-303, 301t, 303t
 descriptions of, 299-300
 endovascular interventions, 305-307, 305t
 nonpharmacologic surgical measures, 255-257
 revascularization operations, 304
 superficial temporal artery to middle cerebral artery anastomosis (extracranial-intracranial [EC/IC] bypass), 304
 Symptoms summaries, 22t
 Syndrome of inappropriate secretion of antidiuretic hormone. *See* SIADH (syndrome of inappropriate secretion of antidiuretic hormone).

 TAIST (Tinzaparin in Acute Ischemic Stroke Trial), 242t-243t, 246t-247t
 Tanne, et al study, 231t
 TCD (transcranial Doppler) ultrasonography, 130-132, 133f
 Teams, acute stroke-care, 24-27, 26t
 TEEs (transesophageal echocardiograms), 88-89
 Tenecteplase. *See* TNK (tenecteplase).
 TGF- β (transforming growth factor- β), 270-271
 Therapy of Patients With Acute Stroke. *See* TOPAS (Therapy of Patients With Acute Stroke) study.
 Thrombin inhibitors, direct, 222t, 250, 290-291
 Thrombolysis, pharmacologic, 223-240
 Thrombolytic agents, 43t, 81, 154-155, 190, 193t, 194-195, 196t, 201, 222t, 223-236, 225t-226t, 228t-229t, 231t, 234f-235f, 252, 274
 Thrombolytic agents, intra-arterial, 236-240, 239t
 Thrombus extraction, endovascular, 255-257
 TIA (transient ischemic attack), 56-57, 58t-61t

 Ticlopidine, 280-281, 280t, 282f-283f, 292t, 295-296
 Time-of-flight sequences. *See* TOF (time-of-flight) sequences.
 Tinzaparin, 242t-243t, 246t-247t
 Tinzaparin in Acute Ischemic Stroke Trial *See* TAIST (Tinzaparin in Acute Ischemic Stroke Trial).
 Tirilazad mesylate, 272
 TNK (tenecteplase), 222t, 240
 TOAST (Trial of ORG 10172 in Acute Stroke Treatment), 242t-243t, 246t-247t
 Tobacco use, 50-51
 TOF (time-of-flight) sequences, 132-133
 TOPAS (Therapy of Patients With Acute Stroke) study, 242t-243t, 246t-247t
 Topical nitroglycerin, 155
 Tranquilizers, major, 184
 Transcranial Doppler ultrasonography. *See* TCD (transcranial Doppler) ultrasonography.
 Transesophageal echocardiograms. *See* TEEs (transesophageal echocardiograms).
 Transforming growth factor- β . *See* TGF- β (transforming growth factor- β).
 Transient ischemic attack. *See* TIA (transient ischemic attack).
 Transient monocular blindness. *See* Amaurosis fugax.
 Transthoracic echocardiograms. *See* TTEs (transthoracic echocardiograms).
 Trauma-related risk factors, 42t
 Treatment windows, 274-275
 Trial of ORG 10172 in Acute Stroke Treatment. *See* TOAST (Trial of ORG 10172 in Acute Stroke Treatment).
 Trials, clinical *See* Clinical trials and research studies.
 Triple-H therapy, 211
 TTEs (transthoracic echocardiograms), 88-89
 T-type and N-type VSCC (voltage-sensitive calcium channel) blockers, 267-268
 Tumors, 197. *See also* Neoplasm.

Vasodilators, 222t
Vasopressors, 158, 206t, 222t, 254
Vasospasm prevention, 206t, 207-211
Venous thrombosis, 42t
Venous thrombosis with secondary hemorrhagic infection, 199-201
Ventricular aneurysm, 36t
Vital signs and general observations, 181
Vitamins supplementation. *See* Supplements (vitamins, minerals, etc).
VSCC (voltage-sensitive calcium channel) antagonists, 266
VSCC (voltage-sensitive calcium channel) blockers, N-type and
T-type, 267-268

Wang, et al study, 231t
WARCEF (Warfarin versus Aspirin in patients with Reduced
Cardiac Ejection Fraction) trial, 286
Warfarin, 89, 280-281, 280t, 282f-283f, 284t-285t, 286, 292, 299
Warfarin versus Aspirin in patients with Reduced Cardiac Ejection
Fraction trial. *See* WARCEF (Warfarin versus Aspirin in patients
with Reduced Cardiac Ejection Fraction) trial.
Warning leak, 57-59, 62t-63t
WARSS trial, 248
West of Scotland Coronary Prevention Study. *See* WOSCOPS
(West of Scotland Coronary Prevention Study).
White cell receptor blockers, 254
Window of treatment, 274-275
Worsening, neurologic, 72t, 176t
WOSCOPS (West of Scotland Coronary Prevention Study), 49t

Ximelagatran, 290-291

ZK200775, 269-270